Iron isomaltoside 1000

Generic Name: Iron isomaltoside 1000

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 1370654-58-2

Unique Ingredient Identifier: 3M6325NY1R

Background: Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

Associated Conditions: Iron Deficiency (ID), Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma
Anemia
Iron-deficiency

Interventions: Drug: Polysaccharide Iron Complex Pill
Drug: Iron Isomaltoside 1000
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 120

Registration Number: NCT05913414

Locations: 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.

Not Applicable

Recruiting

Conditions: Inflammatory Bowel Diseases

Interventions: Drug: Ferrous fumarate
Drug: MonoFer

First Posted Date: 2022-10-14

Last Posted Date: 2022-10-14

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 152

Registration Number: NCT05581420

Locations: 🇳🇱
Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands

Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage

Phase 4

Conditions: Post Partum Hemorrhage
Anemia

Interventions: Drug: Placebo
Drug: Iron Isomaltoside 1000
Drug: Iberet-Folic-500

First Posted Date: 2020-08-10

Last Posted Date: 2020-08-12

Lead Sponsor: University of Malaya

Target Recruit Count: 60

Registration Number: NCT04505514

Locations: 🇲🇾
University of Malaya Medical Centre, Petaling Jaya, Wilayah Persekutuan Kuala Lumpur, Malaysia

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

Completed

Conditions: Iron-Deficiency Anemia
Iron-Deficiency

First Posted Date: 2020-03-24

Last Posted Date: 2023-07-19

Lead Sponsor: Pierre Fabre Pharma AG

Target Recruit Count: 327

Registration Number: NCT04318405

Locations: 🇨🇭
8, Kreuzlingen, Switzerland
🇨🇭
15, Biel, Switzerland
🇨🇭
11, Kreuzlingen, Switzerland

and more 18 locations

Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion

Early Phase 1

Completed

Conditions: Complications

Interventions: Other: placebo
Drug: Iron Isomaltoside 1000

First Posted Date: 2019-08-20

Last Posted Date: 2020-01-22

Lead Sponsor: Ain Shams University

Target Recruit Count: 80

Registration Number: NCT04061655

Locations: 🇪🇬
Ain Shams university, Cairo, Egypt

ProPBM : A Modified Patient Blood Management Protocol

Not Applicable

Conditions: Iron-deficiency

Interventions: Drug: MonoFer

First Posted Date: 2019-03-25

Last Posted Date: 2019-11-01

Lead Sponsor: Ministry of Health, Malaysia

Target Recruit Count: 180

Registration Number: NCT03888768

Locations: 🇲🇾
University Malaya Medical Centre, Jalan Universiti, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Phase 2

Completed

Conditions: Heart Transplant Recipients

Interventions: Drug: Iron Isomaltoside 1000

First Posted Date: 2018-09-07

Last Posted Date: 2021-05-25

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 102

Registration Number: NCT03662789

Locations: 🇳🇴
Oslo university Hospital, Rikshospitalet, Oslo, Norway

Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients

Not Applicable

Completed

Conditions: Knee Arthropathy
Anemia

Interventions: Drug: Iron Isomaltoside 1000

First Posted Date: 2018-03-20

Last Posted Date: 2019-04-18

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 100

Registration Number: NCT03470649

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

CArdio PulmOnary Exercise Testing and IntRAvenous Iron- 'CAPOEIRA-I STUDY'

Completed

Conditions: Anemia, Iron Deficiency
Anemia

Interventions: Drug: MonoFer

First Posted Date: 2017-11-17

Last Posted Date: 2019-09-25

Lead Sponsor: University Hospital Southampton NHS Foundation Trust

Target Recruit Count: 26

Registration Number: NCT03346213

Locations: 🇬🇧
University Hospital Southampton NHS Foundation trust, Southampton, England, United Kingdom

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

Phase 4

Completed

Conditions: Iron Deficiency Anemia of Pregnancy

Interventions: Drug: ferrous fumarate with ascorbic acid
Drug: Iron Isomaltoside 1000

First Posted Date: 2017-06-15

Last Posted Date: 2020-11-13

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 201

Registration Number: NCT03188445

Locations: 🇩🇰
Phamacosmos Investigational site, Hvidovre, Sjaeland, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy